Ipsen tries again in Parkinson’s disease with $363m IRLAB dealFrench drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine Share XIpsen tries again in Parkinson’s disease with $363m IRLAB dealhttps://pharmaphorum.com/news/ipsen-tries-again-in-parkinsons-disease-with-363m-irlab-deal/
Exelixis’ Cabometyx misses survival target in liver cancer trialExelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after Share XExelixis’ Cabometyx misses survival target in liver cancer trialhttps://pharmaphorum.com/news/exelixis-cabometyx-misses-survival-target-in-liver-cancer-trial/
Ipsen’s John Chaddock on making neurotoxins a priority for healthcare systemsInjected neurotoxins can be incredibly potent in treating spasticity from neurological diseases, but the field doesn’t always get Share XIpsen’s John Chaddock on making neurotoxins a priority for healthcare systemshttps://pharmaphorum.com/r-d/views-analysis-r-d/ipsens-john-chaddock-on-making-neurotoxins-a-priority-for-healthcare-systems/
Ipsen’s UK & Ireland MD on adapting business to COVID-19Since entering the pharmaceutical industry as a graduate trainee in the late 1990s, Asad Mohsin Ali’s career has Share XIpsen’s UK & Ireland MD on adapting business to COVID-19https://pharmaphorum.com/views-and-analysis/ipsens-uk-md-on-adapting-business-to-covid-19/
David Loew swaps Sanofi’s top vaccine job for CEO role at IpsenSanofi had no sooner announced the departure of David Loew, its head of vaccines, before he surfaced as Share XDavid Loew swaps Sanofi’s top vaccine job for CEO role at Ipsenhttps://pharmaphorum.com/news/david-loew-swaps-sanofis-top-vaccine-job-for-ceo-role-at-ipsen/
Engaging with customers in a digital worldAs part of our series on customer experience in pharma, in partnership with Indegene, Ipsen’s Paul Murasko explains Share XEngaging with customers in a digital worldhttps://pharmaphorum.com/views-analysis-digital/engaging-with-customers-in-a-digital-world/
Ipsen craters as pricey rare disease drug is put on hold againFrench drugmaker Ipsen’s big-ticket investment in rare bone disease drug palovarotene is looking increasingly like a poor deal, Share XIpsen craters as pricey rare disease drug is put on hold againhttps://pharmaphorum.com/news/ipsen-craters-as-pricey-rare-disease-drug-is-put-on-hold-again/
Allergan gets FDA okay for paediatric Botox useThe FDA has approved Allergan’s Botox to treat lower-limb spasticity in children, further extending the use of the Share XAllergan gets FDA okay for paediatric Botox usehttps://pharmaphorum.com/news/allergan-gets-fda-okay-for-paediatric-botox-use/
Ipsen adds Blueprint’s FOP rare disease drug to pipeline for $535mIpsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a Share XIpsen adds Blueprint’s FOP rare disease drug to pipeline for $535mhttps://pharmaphorum.com/news/ipsen-adds-blueprints-fop-rare-disease-drug-to-pipeline-for-535m/
